Sweden· SE-20130605000014
Xultophy 100 E/ml + 3,6 mg/ml Injektionsvätska, lösning
A medicinal product containing liraglutide + insulin degludec, registered in Sweden by Novo Nordisk A/S.
Checked against Swedish Medical Products Agency (Sweden) on
Informational only — not a medical device.
The record
At a glance
Swedish Medical Products Agency (Sweden)- Active substance
- Liraglutide + Insulin Degludec
- Manufacturer
- Novo Nordisk A/S
- Country
- Sweden (SE)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- Swedish Medical Products Agency (Sweden)
- Last checked
- October 1, 2026
Packs & prices · 1
- se_varunummer20130605000014
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Liraglutide + insulin degludec in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXULTOPHYNovo Nordisk A/S, Bagsvaerd
- NorwayXultophyOrifarm AS
- SpainXULTOPHY 100 U/ML + 3,6 MG/ML SOLUCION INYECTABLENovo Nordisk A/S
- FinlandXultophyNovo Nordisk A/S
- FranceXULTOPHY 100 unités/ml + 3,6 mg/ml, solution injectableNOVO NORDISK (DANEMARK)
- United KingdomXultophy 100units/ml / 3.6mg/ml solution for injection 3ml pre-filled pensNovo Nordisk Ltd
- IrelandXultophy 100 units/mL + 3.6 mg/mL solution for injection.Novo Nordisk A/S
- IcelandXultophyNovo Nordisk A/S*
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Xultophy
- Norway · Xultophy
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swedish Medical Products Agency (Sweden). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c2c79034-ed44-40f3-b165-ad8979f3d835 GET /v1/drugs/c2c79034-ed44-40f3-b165-ad8979f3d835?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "lakemedelsverket",
"doc_types": [
"EPAR",
"EMA"
],
"se_npl_id": "20130605000014",
"product_page": "https://www.lakemedelsverket.se/sv/sok-lakemedelsfakta/lakemedel?id=20130605000014",
"product_doc_link": "https://www.ema.europa.eu/sv/documents/product-information/xultophy-epar-product-information_sv.pdf"
}See everything about liraglutide + insulin degludec.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.